Company news

Orthocell Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Strongest U.S. Remplir Sales Month Since Launch

November 1, 2026

Q1 FY27 OCC Investor Presentation

October 21, 2026

Q1 FY27 OCC Investor Presentation

October 21, 2026

Quarterly Activity Report & Appendix 4C

October 21, 2026

Quarterly Activity Report & Appendix 4C

October 21, 2026

Remplir Shows Excellent Early Prostatectomy Results

October 12, 2026

Orthocell Achieves First Remplir Sales in Thailand

September 20, 2026

Q4 FY26 ASX Investor Presentation

July 13, 2026

Orthocell Appoints Thailand Distributor for Remplir

July 2, 2026

Remplir™: Australian Nerve Repair Device Supports Victims of War in Ukraine

June 28, 2026

First Sales of Remplir Achieved in US$75m Canadian Market

April 29, 2026

Compelling 90% Success Rate for Remplir in Real World Study

April 27, 2026

Q3 FY26 Investor Presentation

April 19, 2026

First Surgical Use of Remplir in US Department of Defense

April 16, 2026

Orthocell Secures Approval to sell Remplir™ to the U.S. Department of Defence Hospital Network

April 16, 2026

OCC Secures Access to 221 U.S. Military Medical Centres

April 14, 2026

Remplir Used in 23 Surgeries in Ukrainian soldiers

March 17, 2026

Orthocell Appoints UK Distributor for Remplir

March 9, 2026

Appendix 4D & Half-Year Financial Report

February 23, 2026

Orthocell Receives $3.0m R&D Tax Refund

February 18, 2026

US Market and Operational Update

February 1, 2026

Quarterly Activity Report & Appendix 4C

January 18, 2026

Orthocell Posts Seventh Straight Record Revenue Quarter

January 5, 2026

Orthocell Hits US Milestone - 100 Remplir Units Sold.

December 17, 2025

Remplir Regulatory Application for US$750m EU-UK Market

December 14, 2025

First Commercial Sales of Remplir Achieved in Hong Kong

December 9, 2025

Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum with ~100 Surgeries Now Performed with Multiple Surgeons Nationwide

November 20, 2025

Remplir gains momentum in nerve-sparing prostate surgery

November 19, 2025

2nd Distributor in Canada, Entire $75m Market Now Covered

November 4, 2025

Remplir Launches in Hong Kong with First Surgical Case

November 2, 2025

HK Distributor Signed as Remplir Expands in the Asian Market

October 28, 2025

OCC Secures Rights to High-Value Bone Regeneration Tech

October 19, 2025

$30m Placement Sees Orthocell Positioned for Rapid Growth

October 16, 2025

Trading Halt

October 14, 2025

Another Record Revenue Quarter for Orthocell

October 1, 2025

First Distributor signed for Remplir in $75m Canadian Market

September 29, 2025

Globally Significant Opportunity Emerges as Remplir™ is used in Nerve-Sparing Prostate Cancer Surgery

September 16, 2025

Remplir Use in Prostate Surgery Signals Global Opportunity

September 15, 2025

Remplir™ Study Delivers Compelling 81% Success Rate

September 8, 2025

Compelling 81% Success Rate for Remplir

September 7, 2025

Appendix 4E & Annual Report

August 29, 2025

Orthocell Announces First US Remplir Sales Revenue

July 9, 2025

Record Revenue of $2.73m in June 25 Quarter up 22.8% QoQ

June 30, 2025

First Surgical Use of Remplir in US$1.6 Billion US Market

June 26, 2025

Compelling Data Highlights Remplir Competitive Advantage

June 18, 2025

Remplir Approved to Commence Sales in the Hong Kong Market

May 11, 2025

12 Distributors Signed for Remplir Covering 21 States in US

May 8, 2025

Remplir Approved to Commence Sales in US$75m Canadian Market

April 29, 2025

Replacement Trading Halt

April 29, 2025

Pause in Trading

April 29, 2025

Older news releases →

Decks

The 5 newest of 35 decks. Every deck is listed under its year.